AB Science has a unique and diversified indication portfolio that includes multiple late-stage programs.

Compound

Indication

Therapeutic area

Preclinical

Phase 1/2

Phase 2b/3

Confirmatory Phase 3

NDA/MAA

Masitinib

AB8939

Amyotrophic Lateral Sclerosis*

Progressive forms of Multiple Sclerosis*

Alzheimer’s Disease*

Indolent Systemic Mastocytosis*

Severe Asthma Uncontrolled with OCS*

Severe Asthma Uncontrolled with ICS*

Pancreatic Cancer*

Prostate Cancer

Moderate and Severe COVID-19

Acute Myeloid Leukemia

Neurology

Inflammatory

Oncology

Viral disease

Oncology

new pipeline for masitinib

*: Positive Phase 2B/3 Results Reported